During the summer months, comparative effectiveness research (CER) sparked a number of conversations among health care stakeholders. There were discussions about a New England Journal of Medicine commentary on the pharmaceutical industry’s ability to communicate health information; the millions of dollars in funding awarded by the Patient-Centered Outcomes Research Institute; and how payers evaluate CER, just to name a few.
We’ll hear more about some of those topics from NPC’s Chief Science Officer Robert Dubois, MD, PhD, who will be co-chairing and presenting at the Fifth Comparative Effectiveness Summit on Sept. 16-18 at the Hyatt Regency Crystal City in Arlington, VA.
Tomorrow afternoon, Dr. Dubois will be leading a discussion on real-world evidence (RWE) and decision-making—how the pharmaceutical industry is partnering with insurers and other health organizations; how RWE is being analyzed and put into use; and what barriers need to be addressed so that optimal use of RWE can occur.
NPC Director of Comparative Effectiveness Research Jennifer Graff, PharmD, also will be at the Summit on Wednesday, moderating a panel discussion on how life sciences companies are using CER. Merck & Co., Inc. Executive Director of Health Policy and Reimbursement Jane Horvath and Boehringer Ingelheim Vice President of Health Economics and Outcomes Research Dr. David S. Memel will discuss how their companies are planning for and considering utilizing the increasing availability of CER evidence.
Be sure to stay tuned as the CER conversation continues later this month by registering for NPC’s September 30 conference, Putting Patients First®: Paving a Path to Useful CER, in conjunction with the National Health Council.